Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Techride -- Ignore unavailable to you. Want to Upgrade?

To: Joana Tides who wrote (3962)	9/8/1999 7:33:00 PM
From: faqsnlojiks	Respond to of 7442

Arrrgh, I sure wish you could made it to Vegas. I know you would have a GREAT time! And to be able to actually meet the incredible Joana Tides...be still my heart!! :*) S'ok though, I'm happy and grateful to know you here on SI, and so we'll drop a buck in the slot, or lay a chip on "lucky 9" for ya'. Tell us what your favorite casino game is, and Carolyn and I will play a hand for you. Wish I could make it to Wall Street to go on a recon mission with you...that sounds like lots of fun! 909's, -Joe

To: Joana Tides who wrote (3962)	9/8/1999 7:35:00 PM
From: Carolyn	Respond to of 7442

Joana - re BINC: Biospherics to Get New Drug Patent on Tagatose September 8, 1999 03:49 PM BELTSVILLE, Md., Sept. 8 /PRNewswire/ -- Biospherics Incorporated BINC , today announced receipt of a Notice of Allowance from the U.S. Patent Office that the Firm is being awarded a patent on the use of tagatose to treat anemia and hemophilia. Dr. Gilbert V. Levin, President of Biospherics and the inventor, said that his discovery included analysis of a 90-day rat study at relatively high dose rates of tagatose. The tagatose improved blood factors in the two diseases and, he stressed, produced no toxic effects. Biospherics officials stated, after discussion with counsel, that the new patent award extends the Firm's royalty-bearing License Agreement with MD Foods Ingredients to the year 2024, five years after expiration of the new patent. Dr. Levin said, "I am delighted with these potentially important new uses. While we have only preliminary results with animals with respect to anemia and hemophilia, a broad beneficial pattern seems to be evolving for the use of tagatose as a drug or drug adjuvant in combating a variety of diseases. This, of course, makes us, and the public, even more eager for MD Foods Ingredients to obtain GRAS (Generally Recognized As Safe) status for the use of tagatose as a food ingredient. With the ability of diabetics to eat tagatose without a rise in blood glucose, and the studies showing significant benefit for tagatose in the treatment of type 2 diabetes, plus its excellent taste and performance as a low-calorie sweetener, tagatose portends a great boon to society." While Biospherics retains drug rights to tagatose use, approvals for drug use would come much later than the pending approval for food use. However, the new results may increase the interest of drug companies in this versatile material. Under its motto, "Technologies for Information and Health," Biospherics' mission is to provide guidance and products to improve the quality of life. Biospherics offers telecommunications call centers, information systems, database management, and proprietary food and medical innovations. Biospherics' Web site is biospherics.com. SOURCE Biospherics Incorporated buygnetandbinc